| Status: Excluded due to NICE appraisal | |
Product meets AWMSG criteria due to NICE appraisal ID5109: Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 50 mg powder for concentrate for solution for infusion |
| Reference number | 5233 |
| Indication | Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/03/2023 |
| NICE guidance | |